Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


p16 status and choice of chemotherapy in the KEYNOTE-040 study - Authors' reply.

Cohen EEW, Soulières D, Swaby RF, Harrington KJ.

Lancet. 2019 Oct 12;394(10206):1323. doi: 10.1016/S0140-6736(19)31264-4. No abstract available.


Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.

Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators.

Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Erratum in: Lancet. 2019 Jan 12;393(10167):132.


A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).

Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW.

Breast Cancer Res Treat. 2017 Sep;165(2):375-382. doi: 10.1007/s10549-017-4310-9. Epub 2017 Jun 16.


Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer.

Partridge AH, Sepucha K, O'Neill A, Miller KD, Motley C, Swaby RF, Schneider BP, Dang CT Jr, Northfelt DW, Sledge GW Jr.

JAMA Oncol. 2015 Jun;1(3):369-74.


Bioequivalence study with lapatinib powder for oral suspension and the original tablet formulation in cancer patients.

Koch KM, Ferron-Brady G, Lemmon C, Cartee L, Hollyfield H, D'Amelio AM Jr, Piepszak A, Swaby RF, Curran D, Arya N.

Clin Pharmacol Drug Dev. 2015 May-Jun;4(3):203-9. doi: 10.1002/cpdd.139. Epub 2014 Oct 27.


CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V.

J Clin Oncol. 2015 May 10;33(14):1564-73. doi: 10.1200/JCO.2014.57.1794. Epub 2015 Jan 20.


Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.

de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, Untch M, Jackisch C, Lang I, Smith I, Boyle F, Xu B, Barrios CH, Perez EA, Azim HA Jr, Kim SB, Kuemmel S, Huang CS, Vuylsteke P, Hsieh RK, Gorbunova V, Eniu A, Dreosti L, Tavartkiladze N, Gelber RD, Eidtmann H, Baselga J.

Lancet Oncol. 2014 Sep;15(10):1137-46. doi: 10.1016/S1470-2045(14)70320-1. Epub 2014 Aug 14.


Five-year local control in a phase II study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer.

Freedman GM, Anderson PR, Bleicher RJ, Litwin S, Li T, Swaby RF, Ma CM, Li J, Sigurdson ER, Watkins-Bruner D, Morrow M, Goldstein LJ.

Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):888-93. doi: 10.1016/j.ijrobp.2012.01.091. Epub 2012 May 12.


Circulating tumor cells in breast cancer: a tool whose time has come of age.

Swaby RF, Cristofanilli M.

BMC Med. 2011 Apr 21;9:43. doi: 10.1186/1741-7015-9-43. Review.


By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy.

Jordan VC, Patel R, Lewis-Wambi JS, Swaby RF.

Breast Cancer Res. 2008;10 Suppl 4:S16. doi: 10.1186/bcr2176. Epub 2008 Dec 18. No abstract available.


Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer.

Swaby RF, Jordan VC.

Clin Breast Cancer. 2008 Apr;8(2):124-33. doi: 10.3816/CBC.2008.n.012. Review.


Clinical utility of circulating tumor cells: a role for monitoring response to therapy and drug development.

Urtishak S, Alpaugh RK, Weiner LM, Swaby RF.

Biomark Med. 2008 Apr;2(2):137-45. doi: 10.2217/17520363.2.2.137.


Development and implementation of a medical oncology quality improvement tool for a regional community oncology network: the Fox Chase Cancer Center Partners initiative.

O'Grady MA, Gitelson E, Swaby RF, Goldstein LJ, Sein E, Keeley P, Miller B, Li T, Weinstein A, Cohen SJ.

J Natl Compr Canc Netw. 2007 Oct;5(9):875-82.


SERMs for the treatment and prevention of breast cancer.

Swaby RF, Sharma CG, Jordan VC.

Rev Endocr Metab Disord. 2007 Sep;8(3):229-39. Review.


Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost.

Freedman GM, Anderson PR, Goldstein LJ, Ma CM, Li J, Swaby RF, Litwin S, Watkins-Bruner D, Sigurdson ER, Morrow M.

Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):347-53. Epub 2007 Mar 26.


Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.

Carvalho MA, Marsillac SM, Karchin R, Manoukian S, Grist S, Swaby RF, Urmenyi TP, Rondinelli E, Silva R, Gayol L, Baumbach L, Sutphen R, Pickard-Brzosowicz JL, Nathanson KL, Sali A, Goldgar D, Couch FJ, Radice P, Monteiro AN.

Cancer Res. 2007 Feb 15;67(4):1494-501.


Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer.

Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC Jr, Mills GB, Fang X.

Cancer Res. 2006 Mar 1;66(5):2740-8.


Importance of rational pre-clinical development: gemcitabine comes of age.

Swaby RF, Bhalla KN.

Cancer Biol Ther. 2005 Aug;4(8):872-3. No abstract available.


Determination of lineage and clonality in diffuse lymphomas using the polymerase chain reaction technique.

Lardelli P, Swaby RF, Medeiros LJ, Jaffe ES, Rizzi R, Stetler-Stevenson M.

Hum Pathol. 1991 Jul;22(7):685-9.


Supplemental Content

Loading ...
Support Center